^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Skin Cancer

    Related cancers:
    1d
    ENO1 Knockdown Impedes Tumour Progression and Promotes Oxidative Phosphorylation in Cutaneous Squamous Cell Carcinoma. (PubMed, Acta Derm Venereol)
    In conclusion, ENO1 knockdown compromises tumorigenicity and promotes OXPHOS. Combining ENO1 inhibition with oxidative-stress-enhancing treatments, such as chemotherapy or radiotherapy, may further enhance efficacy.
    Journal
    |
    ENO1 (Enolase 1)
    1d
    Clinicopathologic and Molecular Analyses of 2 Basomelanocytic Tumors and Literature Review. (PubMed, Am J Dermatopathol)
    CDKN2A and PCTH1 mutations, frequently detected in melanoma and basal cell carcinoma, respectively, were detected in the second case. The presence of 2 components with distinct immunoprofile yet with some common genetic aberration suggests that basomelanocytic tumors may arise from a common progenitor.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KDR (Kinase insert domain receptor) • SOX10 (SRY-Box 10) • KRT17 (Keratin 17) • MLANA (Melan-A) • TP63 (Tumor protein 63) • KRT5 (Keratin 5) • MITF (Melanocyte Inducing Transcription Factor)
    2d
    A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma (clinicaltrials.gov)
    P2, N=100, Recruiting, Iovance Biotherapeutics, Inc.
    New P2 trial
    |
    Amtagvi (lifileucel)
    2d
    Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=92, Recruiting, Aminex Therapeutics, Inc.
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • fulvestrant • Truqap (capivasertib) • AMXT 1501
    2d
    Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer (clinicaltrials.gov)
    P2, N=64, Completed, University of Alabama at Birmingham | N=138 --> 64 | Active, not recruiting --> Completed
    Trial completion • Enrollment change
    2d
    Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (clinicaltrials.gov)
    P2, N=340, Active, not recruiting, Replimune Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    Opdivo (nivolumab) • Tudriqev (vusolimogene oderparepvec-wtpg)
    3d
    SONIB: A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=16, Completed, Melanoma Institute Australia | Recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2025 | Trial primary completion date: Jun 2026 --> Mar 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Odomzo (sonidegib) • Zyclara (imiquimod)
    3d
    The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Mayo Clinic
    New P2 trial
    3d
    Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Emory University | Not yet recruiting --> Recruiting
    Enrollment open
    4d
    Reticulated acanthoma with sebaceous differentiation: A case report. (PubMed, Medicine (Baltimore))
    This rare case highlights the critical role of histopathological examination. Given the limited body of documented evidence for an association between RASD and MTS, documented, albeit limited, baseline immunohistochemistry and colonoscopy should always be considered to rule out MTS in patients diagnosed with RASD.
    Journal
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
    4d
    Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (clinicaltrials.gov)
    P2, N=86, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    Erbitux (cetuximab) • Rybrevant (amivantamab-vmjw)
    4d
    Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss (clinicaltrials.gov)
    P1/2, N=27, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    Keytruda (pembrolizumab) • GSK2636771